CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications
Pharmacogenomics and Personalized Medicine · 2017-07 · Volume 10 · 217-227
DOI: 10.2147/pgpm.s136341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenomics and Personalized Medicine, 2017-07. Verfasst von Jennifer L St Sauver und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences Research. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences Research.
- Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester.
- Center for Individualized Medicine.
- Department of Cardiovascular Diseases.
- Department of Anesthesiology and Perioperative Medicine.
- Department of Laboratory Medicine and Pathology.
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- NHLBI NIH HHS
- NHGRI NIH HHS
- NCI NIH HHS
Zitieren
APA
St Sauver, J. L., Olson, J. E., Roger, V. L., Nicholson, W. T., Black, J. L., Takahashi, P. Y., Caraballo, P. J., Bell, E. J., Jacobson, D. J., Larson, N. B., & Bielinski, S. J. (2017). CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. Pharmacogenomics and Personalized Medicine, Volume 10, 217-227. https://doi.org/10.2147/pgpm.s136341
Vancouver
St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black JL, Takahashi PY, et al. CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. Pharmacogenomics and Personalized Medicine. 2017;Volume 10:217-227. doi:10.2147/pgpm.s136341
BibTeX
@article{StSauver2017,
author = {St Sauver, Jennifer L and Olson, Janet E and Roger, Veronique L and Nicholson, Wayne T and Black, John L and Takahashi, Paul Y and Caraballo, Pedro J and Bell, Elizabeth J and Jacobson, Debra J and Larson, Nicholas B and Bielinski, Suzette J},
title = {CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications},
journal = {Pharmacogenomics and Personalized Medicine},
year = {2017},
volume = {Volume 10},
pages = {217--227},
doi = {10.2147/pgpm.s136341}
}
EUVIMED